medical cannabis applicants are now facing stepped-up federal review after the rescheduling order that prioritized applications submitted during the initial 60-day window. The Drug Enforcement Administration (DEA) has delegated application review to regional field offices and has begun inspections and written information requests across multiple states.
What DEA is doing – Delegation to regional offices: The DEA is routing reviews to local field offices rather than centralizing all intake at headquarters. Regional offices are handling outreach, document collection, and on-site inspections. – Geographic rollout: Most applicants in medical-only states report contact from regional DEA staff. In states with both medical and adult-use programs, most — but not all — applicants have not yet received outreach. – Inspection sequence: DEA review typically follows three stages: (1) initial outreach and requests for documents, (2) on-site physical inspection, and (3) post-inspection follow-up and additional requests.
Common documents and topics requested Regional offices are asking for concrete, operational records that parallel state-level audits. Common requests include: – Corporate structure and beneficial ownership records, including ownership percentages and control agreements – Standard operating procedures (SOPs) for cultivation, processing, distribution, and testing – Names and roles of persons with operational responsibility and copies of position descriptions – Patient verification processes used at dispensaries and medical programs – Evidence of site control, such as leases, deeds, and access agreements – Security protocols, equipment lists, and facility design plans showing cameras, alarms, and access controls – Background checks and employee screening policies, including vendor and contractor screening
Inspections and physical review On-site inspections vary by field office but generally include a perimeter walk, interior walkthrough of storage and production areas, review of security systems, and cross-checking records against SOPs. Inspectors commonly sample employee files, inventory ledgers, SOP documents, and security camera logs. Facilities with both medical and adult-use operations should be prepared to show physical separation or other controls that prevent commingling of medical product.
Manufacturers, cultivators, and Form 225 DEA has not yet opened dedicated application forms for medical-marijuana manufacturers, bulk growers, analytical labs, and distributors, despite announcing that updated forms were coming “in the coming weeks.” Meanwhile, the agency is allowing medical-marijuana cultivators and producers to submit existing DEA Form 225. DEA has told applicants who already filed that there is no need to reapply once the new forms post; the agency will continue processing those submissions.
Practical steps for applicants Based on patterns in regional outreach and inspections, operators can reduce processing delays by preparing the following immediately: – Compile a clear ownership chart with percentages, operating agreements, and any investor pass-through structures – Finalize and index SOPs for all core activities and make them accessible during inspection – Maintain an up-to-date personnel roster showing roles, responsibilities, and dates and results of background checks – Document patient verification procedures and any electronic or manual systems used to confirm eligibility – Produce lease or deed documents and evidence of site control for each licensed location – Audit security systems and evidence of maintenance, camera retention policies, alarm responses, and access logs
Legal and compliance support Several law firms and compliance groups have produced DEA-specific checklists and sample SOPs to align state controls with federal registration requirements. These tools map common DEA document requests to existing state compliance materials to reduce duplication. Operators that already filed under Form 225 should track DEA communications closely; the agency has said it will contact existing filers rather than require reapplication once updated forms appear.
Timing and outlook DEA’s regional inspections are actively underway in many areas. The agency’s promise to publish manufacturer and distributor-specific registration forms “in the coming weeks” has been delayed, and there is no firm public timeline for their release. Given the current approach — regional delegation, document-first outreach, followed by inspections — registrants should expect a phased review that can span several weeks to months depending on the quality and completeness of submitted records.
Bottom line The DEA review process mirrors many state-level compliance checks but adds federal registration requirements that operators must document and demonstrate. Preparing detailed ownership records, SOPs, personnel screening files, site control documents, and security plans now will reduce the likelihood of delays during regional reviews and on-site inspections. Legal and compliance teams can help convert existing state materials into the federal formats that DEA inspectors are requesting.
